Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo. The Food and Drug Administration (FDA) has approved ...
Osteoporosis-related fractures are an important health concern because of related morbidity, mortality, and cost. 2 Bruce Mitlak, M.D., the Chief Medical Officer of Radius, emphasized that "30% of all ...
The labeling for Tymlos (abaloparatide) has been updated to include additional information regarding the mechanism of action (MOA) of the drug. Tymlos, a human parathyroid hormone related peptide ...
Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
The US Food and Drug Administration (FDA) has approved an additional indication for abaloparatide (Tymlos) to increase bone density in men with osteoporosis at high risk for fracture, or in male ...
Tymlos (abaloparatide) is a brand-name injectable medication used to treat osteoporosis. Medicare may cover Tymlos, but coverage and cost depend on the specifics of a person’s plan and how they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results